

Daiichi Sankyo ends influenza vaccine sales deal with Kitasato

30 March 2020 | News

From April 1, 2020, only Daiichi Sankyo will supply Influenza HA Vaccine “Daiichi Sankyo”



Japan based Daiichi Sankyo Company, Limited and Kitasato Pharmaceutical Industry Co., Ltd. have announced the termination of their cooperative sales agreement for Influenza HA Vaccine “Daiichi Sankyo” 1 mL and Influenza HA Vaccine Syringe “Daiichi Sankyo” 0.25 mL and 0.5 mL on March 31, 2020 in Japan.

Daiichi Sankyo and Kitasato Pharmaceutical Industry have strived to expand the utilization of vaccines over many years with the purpose of further improving public health in Japan and expand the availability of preventive medicine. The both companies currently supply 3 vaccines – Influenza HA Vaccine “Daiichi Sankyo”, Freeze-dried Live Attenuated Mumps Vaccine “Daiichi Sankyo” and Freeze-dried Live Attenuated Measles, Rubella Combined Vaccine “Daiichi Sankyo.” However, after a review of sales strategy and discussions, we have reached an agreement to terminate the cooperative sales agreement for Influenza HA Vaccine “Daiichi Sankyo.”

From April 1, 2020, only Daiichi Sankyo will supply Influenza HA Vaccine “Daiichi Sankyo”. However, the cooperative sales agreements for Freeze-dried Live Attenuated Mumps Vaccine “Daiichi Sankyo” and Freeze-dried Live Attenuated Measles, Rubella Combined Vaccine “Daiichi Sankyo” will remain in force and we will continue efforts to expand their utilization.

In order to further improve the health of the Japanese people, the both companies will continue contributing to the enhancement of public health as well as the prevention and treatment of diseases through the manufacture and supply of vaccines and other pharmaceutical products.